How well a coronavirus vaccine might work for older adults has been an open question, because the immune system’s ability to respond to threats declines with age. A vaccine that protects younger adults and children might not work for older adults.

The data Moderna presented today was similar to data from a Phase I trial in younger people that was published in The New England Journal of Medicine in July.

The findings from Moderna’s study have not been peer-reviewed or published in a scientific journal, but the company said it has submitted the results to a peer-reviewed publication.

On Monday, Moderna reached an agreement with the European Commission to buy 80 million doses. Zaks said he expects the company to present Phase 3 trial data for approval to regulators late this year or early next year.

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Buffett’s Kraft-Heinz investment takes another blow – Fox Business

Huntington Private Bank CIO John Augustine discusses what Berkshire Hathaway CEO Warren…

FDA reports 1st drug shortage due to novel coronavirus outbreak – ABC News

Countries around the world are scrambling to respond to the influx of…

SEC Karate-Chops Steven Seagal Over Promoting Cryptocurrency Touted as the Next Gen Bitcoin – Bitcoin News

The U.S. Securities and Exchange Commission (SEC) has charged actor Steven Seagal…